Today we have finalized the third Master Supply Agreement for the sale of API by our client, which supplies CDMOs and pharmaceutical companies worldwide.
Key issues in this kind of agreement are usually the following:
- Forecasts: in particular, how long the binding forecast period should be. Binding forecasts typically cover a period of 6 to 12 months.
- Minimum quantities.
- Lead times.
- Supply of higher volumes: the provisions dealing with the customer’s need for quantities above the forecast, and how to handle a prospective failure by the supplier to meet such demand.
- Breach of contract.
These last points are critical because, in case of supply failure or breach, the customer has to qualify a new supplier, which requires an extensive amount of time.
Another key area of these agreements is intellectual property. Typically, the IP in the finished drug product belongs to the customer, who manufactures and markets the medicine. However, the supplier’s own proprietary IP, such as process know-how, is very often intertwined with it.
For this reason, the agreement should clearly distinguish between background IP, supplier IP and customer IP, and between what is owned and what is merely licensed.
Besides the licence to use the supplier’s IP, at least for the purpose of using the product, it is common to find a commitment by the supplier to grant a licence to the customer and to its designated alternative suppliers or CDMOs, in case of supply failure or breach. This licence is often royalty-free, or at least on pre-agreed terms, and it serves the same purpose mentioned above: allowing the customer to qualify a new supplier quickly.






